Market Place
Sourcing Support
Newron presents H1 2024 results and provides business update
19 Sep 2024 //
BUSINESSWIRE
Newron schizophrenia add-on improves positive, negative symptoms
30 Apr 2024 //
FIERCE BIOTECH
Data from Newron’s Study and An Evenamide Clinical Outlook Presented at The SIRS
08 Apr 2024 //
BUSINESSWIRE
Newron Reports Exceptional One-year Results of Study 014/15 With Evenamide
04 Jan 2024 //
BUSINESSWIRE
Newron Completes Enrollment of Schizophrenia Patients in Study 008A
29 Dec 2023 //
BUSINESSWIRE
Newron to Present Three Posters on Its Clinical Program Evaluating Evenamide
04 Oct 2023 //
BUSINESSWIRE
Newron Reports Compelling Topline Results From All Patients in Study 014
20 Mar 2023 //
BUSINESSWIRE
Newron Reports Striking Results From PII Clinical Trial Evaluating Evenamide
16 Feb 2023 //
BUSINESSWIRE
Newron striking six-month interim results from its exploratory trial evenamide
03 Jan 2023 //
BUSINESSWIRE
Newron provides H1 2022 results and updates on R&D and business activities
15 Sep 2022 //
BUSINESSWIRE
Newron presents encouraging interim results for evenamide in TRS
07 Jun 2022 //
BUSINESSWIRE
Newron Initiates Pivotal Study with Evenamide in Patients with Schizophrenia
06 Sep 2021 //
BUSINESSSWIRE
Tiziana Reports Phase 1 Clinical Data Demonste Oral Treatment with Foralumab
09 Jan 2020 //
BUSINESS WIRE
Newron Receives First Tranche from Financing Agreement with EIB
28 Jun 2019 //
BIOSPACE
Newron Pharmaceuticals S.p.A. Announces Change in the Board of Directors
18 Feb 2018 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.